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Background: Staphylococcus aureus produces several toxins, including Panton-Valentine leukocidin (PVL). The
involvement of PVL in primary skin infections, necrotizing pneumonia, musculoskeletal disorders, brain abscess, and
other diseases, some of which are life-threatening, has been reported. Following expert opinion, we aimed to
provide the tools for establishment of sequence-based diagnostics and therapeutics for those conditions. We
engineered the synergistic S and F (LukS-PV and LukF-PV respectively) pro-toxin subunits from Staphylococcus
aureus USA400 into separate expression E. coli BL21(DE3)-pLysS hosts.
Results: Following Nickel affinity chromatography (NAC), the F subunit came out without bands of impurity. The
S sub-unit did not come off very pure after NAC thus necessitating further purification by size exclusion and
ion-exchange chromatography. The purification plots showed that the BioLogic-LP and AKTA systems are reliable
for following the progress of the chromatographic purification in real-time. Computer predicted Mw for the
6His-LukF-PV and 6His-LukS-PV were 35645.41 Da and 33530.04 Da respectively, while the mass spectrometry results
were 35643.57 Da and 33528.34 Da respectively.
Conclusion: The BioLogic-LP and AKTA systems are commendable for reliability and user-friendliness. As a recent work
elsewhere also reported that a second round of chromatography was necessary to purify the S subunit after the first
attempt, we speculate that the S subunit might contain yet unidentified motif(s) requiring further treatment. The
purified S and F sub-units of PVL were supplied to the Nottingham Cancer Immunotherapy group who used them to
establish sequence-based monoclonal antibodies for diagnostic and therapeutic uses targeting PVL.
Keywords: Staphylococcus aureus, Panton-Valentine leukocidin, Leukocytolytic exotoxin, Chromatography, Mass
spectrometry, Immuno-therapyBackground
Among two-component synergo-hymenotrpoic toxins
associated with the genus Staphylococcus, leukocidin
(Luk), gamma-hemolysin (Hlg), and Panton-Valentine
leukocidin (PVL) have been well documented [1-3]. The
synergo-hymenotrpoic toxins are encoded by distinct
genetic loci [3]. Staphylococcus aureus PVL is encoded
by two co-transcribed genes, lukS-PV and lukF-PV [4]* Correspondence: okolie.charles@lmu.edu.ng
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stated.which reside in the genomes of several bacteriophages
associated with various different strains of S. aureus
[3,5,6]. The active form of PVL requires the assembly of
the two corresponding polypeptides, respectively LukS-PV
and LukF-PV. The prophage harbouring PVL-encoding
genes in S. aureus strain USA400 (also known as S. aureus
strain MW2) is phiSa2MW [7,8].
Originally described in association with pus formation,
carbuncles and furuncles [9], PVL did not receive much
attention in scientific literature because the pathogenicity
of S. aureus was formerly perceived to be restricted to se-
condary infections [10]. PVL-positive S. aureus (PPSA)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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France [11]. Following a report associating PVL with
primary skin infections and pneumonia [12], reports of
the prevalence of primary human diseases associated
with PPSA, including highly contagious therapy-
refractory skin infections and life-threatening haemopty-
sis, have been on the increase all over the world
[13,14].
In Germany, Jung and colleagues reported the case
of a 23-year-old apparently healthy female patient
without any typical predisposing findings who deve-
loped severe sepsis with necrotizing pneumonia and
multiple abscesses following incision of a Bartholin's
abscess [15]. Methicillin-sensitive S. aureus harbouring
PVL genes were cultured from the abscess fluid, mul-
tiple blood cultures and a postoperative wound swab.
Aggressive antibiotic therapy with flucloxacillin, rifam-
picin and clindamycin, drainage and intensive suppor-
tive care lead finally to recovery. In their concluding
recommendation, PPSA strains, should be considered
when a young, immunocompetent person develops a
fulminant necrotizing pneumonia as minor infections,
such as Bartholin's abscess, can precede this life-
threating syndrome. That was probably the first use
of the word “SYNDROME” in the description of
PVL-associated clinical conditions. Other signs and symp-
toms of the PVL-syndrome include multiple organ failure
preceding acute respiratory distress syndrome (ARDS)
such that the victim deteriorate or die rapidly (average:
<72 hours, reports of <24 hours have been documented)
from overwhelming toxicity [15-18]. Other reports
from Germany [13,16], Denmark [17,18], France [19],
Trinidad & Tobago [20] underline the existence of a
"Staphylococcus aureus PVL-syndrome" independent of
susceptibility to meticillin.
Furthermore, the body organs/systems involved in-
cluding the skin, brain, respiratory and musculo-skeletal
organs [21-23], points to PVL as a new worldwide
public health threat. In Spain, a 34-year-old man was
admitted for right parietal brain abscess and thickened
dura mater in close proximity to a lytic bone lesion.
The abscess culture yielded PVL-positive community-
acquired meticillin susceptible S. aureus (PPCAMSSA).
The patient survived after surgery and antibiotic treatment.
This was the first reported case of a brain abscess due to
PPSA [24]. In Egypt, a 50-year-old man was diagnosed with
brain abscess associated with PVL-positive community ac-
quired-MRSA (PPCAMRSA) in April 2007; following two
intensive care admissions, his death was reported at the
end of July 2007 [25]. Survivors of PVL-syndrome often
go through rigorous intensive care [15,23,25,26]. Other
than the 50-year old Egyptian man, the victims of PVL
syndrome are often young healthy persons, including
school children (mean age = 20) [14,15,17].Molecular characterization have shown that PVL-
positive S. aureus (PPSA) belong to different genotypes
[27] and could be acquired from the community
[16,25,27] as well as from the hospital [21]. Convention-
ally optimal medication and management is not effectual
and no therapeutic preparation is particularly successful
[26,28] as gold standard treatment is lacking [29,30].
Treatment is further complicated because the outcomes
of PVL-associated conditions are independent of S. aureus
meticillin susceptibility, while expert opinion signals bleak-
ness “Until the toxins and inflammatory intermediaries
responsible for the necrosis can be neutralised earlier,”
[29,30].
The use of immune bodies for the treatment of toxic
S. aureus infection has been reported, including septi-
caemia which was successfully treated with immune
blood [31]. Therefore there is hope for immunoglobulin
therapy. Human polyclonal immunoglobulin containing
anti-PVL antibodies (TégélinR) was proposed as a poten-
tial treatment for PVL necrotizing pneumonia [32]; but,
not much was reported subsequently of Tegelin. Thus
the need for rapid and specific therapy against PVL syn-
drome, and the attendant rapidity of victim deterio-
ration, remains to be met.
To provide the tools for the establishment of thera-
peutic monoclonal antibodies as indicated by expert
opinion, we cloned the two genes (lukS-PV and lukF-PV)
coding for LukS-PV and LukF-PV respectively from
S. aureus USA400 into two separate expression E. coli
BL21(DE3)-pLysS host systems from which we sub-cloned
each of them into two separate expression E. coli host
systems. Following expression of the constructs, which
we confirmed using Coomassie stained sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
gels, the pro-toxins were purified by chromatography. The
molecular masses of the purified peptides were determined
by electrospray ionization–time-of-flight (ESI–TOF) mass
spectrometry.
Methods
Gene cloning and expression protocols and reagents
Except otherwise stated, gene cloning and protein ex-
pression protocols were based on standard molecular
cloning textbook [33] with few modifications.
Bacterial strains and plasmids used for Recombination
The bacterial strains and plasmids used for recombi-
nation are described in Table 1.
Cultivation of bacteria and extraction of bacterial
genomic DNA
Due to the unascertained risk level of S. aureus strain
USA400 (also called MW2), isolation and DNA extraction
were performed in biosafety level 3 (BSL3) containment
Okolie et al. BMC Biotechnology 2013, 13:103 Page 3 of 13
http://www.biomedcentral.com/1472-6750/13/103laboratory designated for work with pathogens sus-
pected to be potentially hazardous. It is required by
CDC and NIH guidelines that when uncertain of the
risk level, a presumably higher protection level should
be applied [35]. Sterile disposable loop was used to
touch frozen culture and plated out on brain heart
infusion (BHI) agar. Following overnight incubation
(18-28 hours) at 37°C, genomic DNA was extracted
from the grown cultures by suspending four discrete
colonies in 1.0 ml of molecular grade nuclease-free
water (Sigma, UK) in a 1500 μL PCR grade eppendorf
tube (Eppendorf, Germany). The tube was heated (98°C,
10 minutes) and then centrifuged (13000 g, 30 seconds)
in an Eppendorf benchtop microcentrifuge (Eppendorf,
Germany). The supernatant was taken out of the
level 3 suite and used for PCR in the general (BSL2)
laboratory.PCR amplification of recombinant lukS-PV and lukF-PV
from S. aureus USA400
Suitable primer sequences were identified within the
lukS-PV and lukF-PV genes of the PVL coding region
of S. aureus strain MW2 (GenBank BA000033). The
5´ primers were chosen within the coding sequence
of each gene, omitting the region predicted to encode
the signal peptide as published for PVL [4] and veri-
fied online (http://www.cbs.dtu.dk/services/SignalP/).
On account of previous success in our laboratory
[34], we replaced the signal sequence of each pro-
toxin subunit with NcoI sequence, which inserts a
methionine start codon; we also replaced the stop co-
dons with XhoI sequence, which enables the insertion
of 6His-tag to allow for interactions between poly-
histidine fusion tags and immobilized metal ions forTable 1 Bacterial isolates and plasmids used for genetic
engineering
Identification Genetic
property
Source
S. aureus
MW2
(USA400)
PVL-positive
CA-MRSAa
Network on antimicrobial resistance
in Staphylococcus aureus (NARSA)
pGEM®-T Easy
Vector
Intermediate
plasmid vector
Lab stock maintained by Dr. Philip
Bardelang [34]
Escherichia
coli DH-5α
Intermediate
E. coli host
pET-21d(+) Protein
expression
plasmid vector
E. coli BL21
(DE3)pLysS
Protein
expression
E. coli host
a CA-MRSA is short for Community acquired meticillin resistant
Staphylococcus aureus.protein purification. The 3' primers encompassed the
stop codon of each gene. NcoI site (C/CATGG) was
engineered into the primer sequence for the 5'
primers (rlukS-PV-1 and rlukF-PV-1) and Xho1 site
(C/TCGAG) was engineered into the primer sequence
for the 3´ primers (rlukS-PV-2 and rlukF-PV-2). We
used Pwo DNA polymerase for PCR high yield and
fidelity.
Separate cloning of DNA fragments into intermediate
E. coli host system
The two recombinant DNA fragments amplified from
S. aureus MW2 were separately TA ligated with inter-
mediate vector pGEM®-T Easy (Promega, Madison,
USA). Since the DNA fragments were blunt-ended
PCR products of high fidelity Pwo polymerase, Taq
DNA polymerase was used for 3’-A tailing to allow
for ligation with the complementary T projecting
from the pGEM®-T Easy plasmid. To allow for 3´-A
overhangs necessary for the TA cloning principle of
the pGEM®-T Easy vector, 3’-A tailing by Taq DNA
polymerase is often performed in our laboratory.
Briefly, gel-purified PCR product (4 μL) was trans-
ferred into a 200 μL PCR tube maintained on ice and
containing thermopol buffer (2 μL), 1.0 μM of d’ATP
and 5 units of Taq polymerase (Roche, Germany) all
in a total volume of 10 μL. The mixture was vortexed
for thorough mixing and incubated on the cycler (72°C,
10 minutes) to enable 3´-A tail. The resulting 3´-A
tailed reaction was placed on ice and used immediately
for ligation reaction with pGEM®-T Easy plasmid. Ali-
quot (2 μL) of the ligation was transformed into Escheri-
chia coli 5α and subsequently plated out on Luria-
Bertany (LB) agar containing ampicillin (100 μg/mL)
and X-gal (40 μg/mL) for easy distinguishing of recom-
binant (white) colonies from non-recombinant (blue)
transformant colonies with further confirmation by PCR
amplification.
Sub-cloning of separate insert DNA fragments from
intermediate E. coli host system into expression E. coli
host system
One white colony of the transformant from recom-
binant E. coli clones was subcultured in LB broth
(Difco Laboratories, Detroit, MI) to obtain plasmid
miniprep which was purified using Wizard® SV system
(Promega, USA). Each separate fragment of insert
DNA (S or F subunit) was released from the inter-
mediate plasmid DNA (pGEM®-T Easy plasmid vec-
tor) by double-digest of the miniprep. The double-
digest reaction (40 μL) contained 15 uL of the inter-
mediate plasmid miniprep, 4 μL of X10 multicore
buffer (promega, UK), 4 μL of X10 Bovine Serum Al-
bumin (Promega, UK) and 0.5 μL of NcoI (NEB, UK)
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incubated for 4 hours at 37°C. The expression plasmid
vector pET-21d (+) (Novagen, USA), was gated and li-
nearized by the same double-digest. Following digests,
the restriction digest enzymes were inactivated by heat-
ing at 65°C for 15 minutes according to manufacturer’s
instructions. Shrimp alkaline phosphatise (SAP), accor-
ding to the manufacturer’s instruction (Promega, UK),
was used to prevent the linearized vector plasmid from
recircularizing. Briefly, 20 μL from the 40 μL doubly-
digested pET-21d(+) was transferred to a fresh sterile
500 uL Eppendorf tube and made up to 25 μL of de-
phosphorylation mix by adding 3.0 μL of SAP 10X reac-
tion buffer (equivalent to 50 mM Tris–HCl, pH 9.0 at
37°C, and 10 mM MgCl2) and then 1.0 μL equivalent to
1.0U of SAP. Dephosphorylation was incubated at 37°C
for 1 hour. SAP was inactivated by heating at 65°C for
15 minutes. The inserts were then ligated separately
with the expression plasmid vector using T4 DNA ligase
(NEB, UK). Each ligation reaction for the expression
contained 2 μL of the digested insert, 2 μL of pET cut
with the same RDEs, 1.0 μL of X5 DNA buffer, 5.0 μL of
X2 ligase buffer and 1.0 μL of T4 DNA ligase. The
ligation reaction was incubated on the Eppendorf cycler
at 22.5°C for 5 minutes. The contents of the ligation re-
action tube were concentrated to the bottom of the tube
by centrifugation (30,000RPM, 1 minute). A volume of 4
uL of the ligation reaction was used to transform one
aliquot of expression E. coli BL21(DE3)-pLysS cells
(Invitrogen, Paisley, UK). The transformation reaction
was maintained on ice for 30 minutes and heat-shock at
42°C for 45 seconds and returned to ice for 2 minutes.
Pre-warmed LB broth (400 μL at 37°C) was added to the
transformation reaction which was then maintained at
37°C for 90 minutes in the shaker incubator. Aliquots
(20 μL) were then plated out on LB agar supplemented
with ampicillin (100 mg/L) and incubated overnight
(24 hours). Growth on ampicillin was used as evidence
of successful transformation. Transformant E. coli
clones were further confirmed by PCR. The resulting
plasmids were transformed into the expression E. coli
BL21(DE3)pLysS and plated out on LB agar containing
ampicillin (100 μg/mL). Growth on LB agar containing
ampicillin (100 μg/mL) was was the phenotypic evi-
dence of successful transformation.
Structural confirmation of fusion DNA and translated
peptide sequences
Transformant expression E. coli clones were further con-
firmed by PCR amplification and sequencing of the ap-
propriate DNA insert (rlukS-PV and rlukF-PV) from the
respective expression E. coli hosts using the same
primers engineered with NcoI and XhoI sequences with
which the template DNA was amplified from S. aureusMW2 at the beginning of the cloning experiment. To con-
firm the structural integrity of each reading frame, includ-
ing the insertion of the N-terminal T7-Tag® sequence and
the C-terminal 6His-Tag® sequence, we sent the purified
plasmids to Cambridge Geneservice (http://www.geneser-
vice.co.uk/home/) for sequencing as we did not have the
necessary sequencing primers in Nottingham at the time.
We then used the sequence translation tool at the
European Bioinformatics Institute (transeq) to translate
the nucleotide sequences from Geneservice into peptide
sequences.
Expression of recombinant proteins
Transformant E. coli clone (1 discrete colony), con-
firmed by PCR and sequencing, was picked into 200 mL
of 2x YT broth in a 2 Litre flask and shaker-incubated at
35°C for 5 hours to mid-log phase (OD600nM = 0.7).
Uninduced control (1.0 mL) was removed for SDS-
PAGE before adding isopropyl–D-thiogalactopyranoside
(IPTG) stock of 839 mM (Fisher, UK) to achieve a
1.0 mM final concentration. The induction was incu-
bated at 30°C with shaking at 200 rpm for 4 hours in a
Model G25 controlled environment incubator shaker
(New Brunswick Scientific, USA). An aliquot (10 μl) di-
luted in equal volume of double strength SDS loading
buffer was tested on SDS-PAGE to confirm induction
using prestained protein marker as a guide of protein
size. Protein expression E. coli cells were spun down
(13,000RPM, 1 minute) using Eppendorf bench top cen-
trifuge. After discarding the supernatant, the cell pellet
was dissolved in 100 uL of 2x SDS-PAGE loading buf-
fer and heated on the cycler for complete lysis (98°C,
3 minutes) followed by another spin at 13,000RPM for
2 minutes. Using pre-stained protein marker to ascertain
protein size, an aliquot of the protein rich supernatant
(10 μL) was loaded onto a 10% SDS resolving gel
through a 6% stacking gel. The gel was run first at 150 V
for 15 minutes settling the samples at the interphase
between the stacking gel and the resolving gel and then
at 175 V for further 30 minutes. The gel was stained
with Coomassie stain for 2 hours and then transferred
to fast decolorizer for 30 minutes and finally transferred
to and left overnight in slow destain. After overnight
slow destain, the images were viewed under the white
light (UVP, Cambridge, UK).
Bioinformatics predictions prior to purification of S and F
proteins
Bioinformatics tools were used to predict the theoretical
iso-electric point (pI) and molecular weight (Mw) of
both proteins. The direct strand of the nucleotide se-
quence for each protein subunit including the six histi-
dine moieties were translated into protein using the
nucleotide-protein translation tool (http://www.ebi.ac.
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European Bioinformatics Institute (EBI). To infer the
structural bioinformatics image of the two pro-toxins,
we entered the sequences obtained from transeq into
the protein structure prediction server (PS)2 (http://ps2.
life.nctu.edu.tw/) provided online by the National Chiao
Tung University Molecular Bioinformatics Centre. PS2
is an automated homology modelling server. The
method uses an effective consensus strategy by combi-
ning PSI-BLAST, IMPALA, and T-Coffee in both tem-
plate selection and target-template alignment. The final
three dimensional structure is built using the modeling
package MODELLER [36].
Preparation of his-tagged pvl protein subunits for
chromatographic purification
Following transeq translation, the theoretical pI and Mw
of the protein subunits were computed by entering the se-
quences of single letter protein codes into the pI analysis
tool at EXPASY (http://www.expasy.org/tools/pi_tool.
html). Preparation of His-tagged PVL protein subunits
followed a protocol used in our laboratory for other pro-
tein work [34,37], with modifications. Briefly, the bulk of
the E. coli cells expressing the fusion proteins pelleted and
saved at -80°C were gently resuspended in 30 ml cold
charge buffer (20 mM Imidazole pH 7.0, 50 mM NaCl,
10% (v/v) glycerol, 1 mM PMSF) and then sonicated on
ice for 20 minutes (intermittent 15 seconds bursts of 10
microns) using Soniprep 150 Plus Ultrasonic Disintegrator
(MSE, London, UK). Two successive 30 minutes centrifu-
gations at 18000 g were used to clear the cell lysate of
insoluble cell debris ready for purification by Nickel
affinity (Ni++-affinity) chromatography.
Purification of his-tagged pvl protein subunits by
nickel-affinity chromatography
Nickel-affinity chromatography (NAC) was performed
using fast protein liquid chromatography (FPLC) system
(BioLogic LP: Bio-Rad, USA). A communal protocol
used for Ni++-affinity FPLC in our laboratory [38], was
used for this study, with some modifications. The
schema of the FPLC programme is detailed in Table 1.
Briefly, a 5 mL HiTrap chelating HP column, Code
Number: 17-0409-01 (GE Healthcare, Amersham
Biosciences, Buckinghamshire, UK) was charged with
Nickel using a single 20 ml injection of 50 mM NiCl2,
equilibrated in buffer A (25 mM NaH2PO4 pH 7.0, 0.5 M
NaCl, 5% (v/v) glycerol, 2 mM imidazole), then buffer B
(25 mM NaH2PO4 pH 7.0, 0.5 M NaCl, 5% (v/v) glycerol,
1 M imidazole), finally buffer A again. Solid NaCl was
added to the cleared cell lysate to a final concentration of
0.5 M and the sample applied to the column at a flow-rate
of 1 ml/min. The loaded column was washed in 5% buffer
B (15 mL), which is 95% buffer A, until no unboundproteins eluted from the column which is monitored in
real-time via the chromatogram generated by the BioLogic
LP software. Bound proteins were eluted from the column
using a linear gradient of 5-85% buffer B in a total volume
of 40 ml. The purity and relative Mw of the fusion
proteins were assessed by SDS-PAGE (10%).
Preparation of rLukS-PV for further purification by ion
exchange chromatography
The protein was dialysed overnight in buffer A (10 mM
Tris, 50 mM NaCl, pH 7.0) using 8000 pore membrane
(Millipore, UK). All buffers and solutions intended to run
through the system, including water, were degassed before
they getting in contact with the AKTA Explorer system.
Purification by ion exchange chromatography
Ion exchange chromatography (IEC) was performed using
ÄKTA™ Explorer 10 FPLC (Amersham Pharmacia Biotech,
USA) driven by UNICORN 4 software. The buffers and
protocol are similar to those described elsewhere [38,39].
Briefly, the contents of the tubes bearing the S-subunit
were pooled together and loaded into the AKTA Explorer
FPLC system. The S-loop was filled with degassed double
distilled water and attached to the system. The IEC was
programmed to bind protein in low salt buffer A (same
buffer A used for NAC) and elute in high salt gradient
IEC buffer B (10 mM Tris, 1.0 M NaCl, pH 7.0). Buffer A
was the donor of positive charge, while buffer B is the ion
exchange gradient buffer. Use of Mono S column for IEC
had been described elsewhere [39]. Briefly, following a sys-
tem wash, the protein was injected into the sample inlet of
the ÄKTA™ explorer while buffers A and B were loaded
into inlets A11 and B1 respectively. The Mono S column
was attached to the nozzle between valves V2 and V3
when V2 and V3 were in position 2. The alarm monitors
were set to a limit of 3.2 MPa and enabled. The flow-path
for the column position was set to position 2. Degassed
double distilled water was allowed to flow through the co-
lumn at a rate of 1 ml/minute for 5 minutes. Another sys-
tem wash was performed. Water was replaced with buffer
A into inlet A11 and buffer B into inlet B1. The protein in
buffer A was loaded into the S-loop. The chromatography
was performed by allowing the contents of the S-loop
to load unto the column at a rate of 1.0 ml/minute.
Further Purification of rLukS-PV by size exclusion
(gel filtration) chromatography
Except for the few differences in instrumentation men-
tioned below, the protocol and reagents used for size exclu-
sion chromatography (SEC) and for the IEC were the same.
We replaced the Mono S column used for IEC with a His-
Prep™ Superdex 30 column previously used in our labora-
tory for SEC of protein sizes similar to the 6His-LukS-PV
[34,37]. HisPrep™ columns are designed for scaling up the
Table 2 Primers designed in this study and used for
recombination
Primer
Ida
Primer sequence in 5′→ 3′
directionb
Amplicon
(Size in bp)
rlukS-PV-1 GGC/CATGGATAACAATATT
GAGAATATTGGTGATGG
rlukS-PV (868 bp)
rlukS-PV-2 GGCC/TCGAGATTATGTCC
TTTCACTTTAATTTCATGAG
rlukF-PV-1 GGCC/CATGGCTCAACA
TATCACACCTGTAAG
rlukF-PV (919 bp)
rlukF-PV-2 GGCC/TCGAGGCTCATAGGATT
TTTTCCTTAGATTGAG
a Primer identification.
b RDE sequences bold and underlined.
Okolie et al. BMC Biotechnology 2013, 13:103 Page 6 of 13
http://www.biomedcentral.com/1472-6750/13/103purification of His-tagged proteins and have 1/16" fittings
for convenient use on the ÄKTA™ Explorer FPLC system.
Results and discussion
Recombinant lukS-PV and lukF-PV generated from
S. aureus MW2
Primer sequences used for the amplification of rlukS-PV
and rlukF-PV from the S. aureus MW2 DNA are pre-
sented in Table 1. PCR primers were synthesised by
SigmaGenosys (Sigma, UK). DNA fragments (rlukS-PV
and rlukF-PV) amplified from S. aureus MW2 are shown
(Figure 1A). For easy identification, the rlukF-PV fragment
is the larger amplicon (Lanes 1 and 2, 919 bp), while the
rlukS-PV is the smaller amplicon (Lanes 4 and 5, 868 bp),
thus easily giving clue of successful and reliable amplifica-
tion of the two DNA fragments. Amplification errors can
be mistaken for polymorphisms or mutations and loss of
PCR amplification product or wrong size is not unusual in
gene cloning work. We were very careful to use optimally
working PCR inputs, including high fidelity proofreading
Pwo DNA polymerase and fresh template DNA. Impor-
tantly too, the design of the oligonucleotide primers was
done with much precision. Also, we avoided carryover of
DNA from other experiments as sequencing results and
blastn showed 100% specificity in the lengths and nucleo-
tide contents of the amplified fragments. The success of
the experiments at this primary stage was crucial to the
generation of the recombinant DNA for engineering into
the intermediate E. coli host systems.
Sub-cloning of insert rlukS-PV and rlukF-PV from
intermediate system into expression system confirmed by
culture and PCR
The plasmids used for this work are listed in Table 2.
Since the pGEM®-T Easy Vector harbours Ampr gene1   
Gel A     PCRs
L         1       2        3       4      5
DNA size (bp)
200
300
400
500
600
700
800
900
1000
Figure 1 Start-up amplification and restriction digests of rlukS-PV and r
MW2 template genomic DNA. Lane L, 100 bp DNA Marker (NEB, UK); Lanes 1
negative control; Lanes 4 and 5 rlukF-PV, 919 bp. B. Double digests (NcoI and
to release the insert DNA fragments. Lane 1, Undigested pGEMT-Easy-rlukF-PV
rlukF-PV below the 1.0 kb mark; Lane 3, Duplicate of lane 1; Lane 4, Duplicate
pGEMT-Easy-rlukS-PV showing the cleaved insert rlukS-PV, below the 1.0 kb m
Undigested pET expression vector; Lane 10, pET vector cut with NcoI and Xho
Molecular grade water; Lane L, 1 kb DNA Marker (NEB, UK).which confers ampicillin resistance, the presence of the
insert within the intermediate host system was confirmed
by growth on LB agar supplemented with amplicillin
(100 μg/mL). Transformants were further confirmed by
PCR amplification of each insert from the respective
intermediate host system. The amplicons were the same
as in Figure1A (no need repeting images). Following the
cleaving of the insert DNA fragments of rlukS-PV and
rlukF-PV off the miniprep of the intermediate host sys-
tem using NcoI and XhoI RDEs (Figure 1B), the DNA
fragments were ligated with pET-21d(+) which had been
restricted with the same NcoI and XhoI. In principle, a
molecule of the DNA insert ligated into a molecule of
the restricted and linearized plasmid vector and kept gated
by dephophorylation. Following ligation, the insert frag-
ment becomes integrated into the plasmid vector which
becomes recircularized as illustrated with the lukF-PV
fragment (Figure 2A). Following the ligation of the plas-
mids with the insert DNA fragments, the ligation pro-
ducts were separately transformed into E. coli BL210.5
DNA size (kb)
1.0
1.5
2.0
3.0
4.0
Gel B     RESTRICTION  DIGESTS   
   2     3     4     5      6     7     8     9    10   11    L       
lukF-PV. A. PCR amplification of rlukS-PV and rlukF-PV from S. aureus
and 2, rlukS-PV, 868 bp; Lane 3, Molecular grade water used as PCR
XhoI) of minipreps of the intermediate host E. coli 5α-pGEMT-Easy-luk-PV
; Lane 2, Digested pGEMT-Easy-rlukF-PV showing the cleaved insert
of lane 2; Lane 5, Undigested pGEMT-Easy-rlukS-PV; Lane 6, Digested
ark; Lane 7, Duplicate of lane 5; Lane 8, Duplicate of lane 6; Lane 9,
I (the next home of the cleaved insert DNA fragments); Lane 11,
Figure 2 Reconstruction and amplification of rlukS-PV and rlukF-PV from protein expression system. A. Gene map of pET-21d(+)-lukF-PV
(Reconstructed using VECTOR NTI software). The insert (rlukF-PV) locates within the NcoI and AvaI RDE sites, technically between the T7 promoter
and terminator, all confirmed by sequencing. NOTE: The VECTOR NTI prefers the non-specific nuclease (AvaI), which recognises the degenerate
sequence (CYCGRG), over the specific XhoI used in the cloning experiments which specifically recognises the sequence (CTCGAG) engineered into
the primers used for recombination. B. Amplification of rlukS-PV and rlukF-PV from the expression system. Lane 1, rlukS-PV amplified from
expression E. coli BL21(DE3)-pET-21d(+)-lukS-PV; Lane 2, rlukF-PV amplified from expression E. coli BL21(DE3)-pET-21d(+)-lukF-PV; Lane 3,
Molecular grade water used as negative PCR control; Lane 4, 100 bp DNA ladder.
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the transformant E. coli BL21(DE3)pET-rlukS-PV and
E.coli BL21(DE3)pET-rlukF-PV on LB agar supple-
mented with ampicillin (100 μg/mL). Further con-
firmation was based upon the amplification of the
appropriate PCR products from the isolated colonies of
the expression E. coli hosts (Figure 2B). Proof of trans-
formation has been successful elsewhere by ampicillin
agar cultures [38,40] and genomic PCR of the transfor-
mant colony for the insert DNA [41].
Nucleotide sequencing confirms the structural integrity of
the reading frames
Nucleotide sequence of the recombinant DNA amplified
from the expression E. coli genome (Additional file 1 and
Additional file 2) and the translated protein products for
respective fusion proteins are presented (Additional file 3
and Additional file 4). At this stage of the experimentation,
establishment of clones with perfect (100%) identity, were
very encouraging for us to rule out mutations which could
generate aberrant proteins. Ranging from the stringency
of the Pwo used for initial amplification of the recombi-
nant DNA, through every step of the cloning, we are
pleased with the outcome. The accuracy in size and struc-
ture of the sequences are good rewards for all the effort.
SDS-PAGE shows over-expression and relative sizes of S
and F protein subunits
SDS-PAGE showed clear differences in the purity and
relative molecular sizes of the two proteins (Figure 3A).
The 6His-LukS-PV located approximately at the 33 kDamark while the 6His-LukF-PV band was definitely above
the 33 kDa mark. This inference corroborates previous
reports elsewhere which documented the relative mo-
lecular sizes of 34 kDa and 33 kDa for LukF-PV and
LukS-PV respectively [3,4]. Interestingly, lanes 2 and 3
of Figure 3A showed very strong expression of the F
subunit, while lanes 4 and 5 show expression of the S
subunit, though not as strong as F expression. Whereas
the concentration of IPTG used and the duration of in-
duction were the same for both proteins, whatever might
be responsible for the obvious difference in the expres-
sion of the two proteins is yet unknown to us. However,
the major essence is that both proteins showed over-
expression and availability for purification.
Protein purification by nickel-affinity chromatography
shows dissimilar yields
The protocol for Ni++-affinity chromatography is sum-
marized schematically in Table 3. The SDS-PAGE of lys-
ate and eluate following Ni++-NTA chromatography of
6His-LukS-PV and 6His-LukF-PV are shown (Figure 3B
and C). The F subunit came out of the Ni-affinity chro-
matography with no band of impurity (Figure 3B), while
the S subunit had bands of impurity above and below
the expected protein band. We do not know if the ex-
pression patterns of the proteins contributed to the vari-
able purification efficiency of NAC which is obvious in
Figure 3. Similar reduced efficiency of purification of
LukS-PV was reported following a work in which both
the S and F subunits were purified from lysates of S.
aureus USA300 and USA400; they had to perform a
Figure 3 Expression and Ni++-affinity purification of S and F protein subunits. A. Over-expression of fusion LukS-PV and LukF-PV (10% SDS-PAGE)
Lane 1, Protein Mw standard; Lanes 2 & 3, Total soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukF-PV after induction with IPTG; Lanes 4 & 5, Total
soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukS-PV after induction with IPTG; Lane 6, Uninduced E. coli BL21(DE3)-pET-21d(+)-lukS-PV; Lane 7,
Un induced E. coli BL21(DE3)-pET-21d(+)-lukF-PV. 3B and C. Purity of His-Tagged LukS-PV and LukF-PV following Nickel Affinity chromatography.
B. Lane 1, Total soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukF-PV after induction with IPTG; Lane 2, Purified 6His-LukF-PV; Lane 3, Protein Mw
standard. C. Purity of His-Tagged LukS-PV following Nickel Affinity chromatography. Lane 1, Protein Mw standard; Lane 2, Total soluble lysate of E. coli
BL21(DE3)pLysS-pET-21d(+)-lukS-PV after induction with IPTG; Lane 3, water; Lanes 4, 5 & 6, Eluate without His-Tagged LukS-PV; Lanes 7, 8, 9 & 10, Eluate
containing His-Tagged LukS-PV.
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is the second report of such reduced purification effi-
ciency. It is possible that some yet unidentified amino
acid moieties within the sequence of the S protein
have the capacity to reduce the efficiency of purificationTable 3 Schema of the Ni++-NTA fast protein liquid
chromatography programmea,b
Step Volume (mL)c Solutiond
01 00 - 20 De
02 20 - 40 Cf
03 40 - 60 A
04 60 – 90 E = Protein
05 90 – 115 A
06 115 – 130 Mix 5% B
→ 120 Collect 2 mL
07 130 - 180 Gradient of 5 to 100% B
08 180 - 200 B
→ Divert to waste
End of method, washing up of the machine, and log off
→ No necessary information. Proceed to the shown step.
a The flow-rate was 1.0 mL throughout the entire run.
b The entire programme was 200 mL.
c Increase on the tabulated volumes were always allowed by pushing the Hold
(H) button on the machine. This accounts for the ‘H’ on the BioLogic LP output
during the run.
d All solutions were filtered and degassed.
e Solution D is sterile distilled water.
f Solution C is the charge buffer.of the S protein by currently known technology.
Though that was not the theme of our experiments,
but in observing that it has happened to other re-
searchers before us, we would like to suggest that fu-
ture attempt at resolving such issues might be helpful
to the scientific community. On the chromatogram
generated by the BioLogic LP software during the puri-
fication (Figure 4), the value of the absorbance unit
(AU), graduated in blue colour on the left hand side
bar of the vertical axis of the chromatographic purifi-
cation plot, which stood at 0.8922 showed that the
concentration of His-tagged protein eluting from the
system was low (Figure 4A). The purification plot for
rLukF-PV showed that the AU was at the maximum
mark of 5.0000 (Figure 4B) which is the highest pos-
sible output by the BioLogic LP software, an evidence
that the F subunit eluted with reckonably high con-
centration of His-tagged protein. The difference might
have to do with the obvious difference in the over-
expression of the two proteins (Figure 3A). Having
treated the two proteins to the same buffers and
protocol, we were unable to explain why the F sub-
unit came off the Ni++-affinity chromatography re-
quiring no further purification protocol as no band
of impurity was seen on the SDS-PAGE (Figure 3B),
whereas the S subunit had several bands of impurity
(Figure 3C). Interestingly, a recent report showed that
the S subunit purified by ion-exchange chromatography
Figure 4 BioLogic LP chromatogram during Ni++-affinity chromatographic purification of 6His-LukS-PV (upper) and 6His-LukF-PV (lower)
in real-time. NOTE: AU = Absorbance unit, mS/cm = conductance of mobile phase. The inscriptions within the blue circles are the operational mode,
i.e., S = start, H = hold, P = Pause, C = continue, and E = end. 6His-LukS-PV purification: The sign-post shows a low concentration of protein (0.8922 AU)
in the eluate. B 6His-LukF-PV purification: The sign-post shows a high concentration of protein (5.000 AU) in the eluate.
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raphy [42].
Ion exchange chromatography removes some impurity
from fusion LukS-PV
The characteristics of the Mono S column used for
IEC are described in Table 4. Those characteristics were
compatible with the ÄKTA™ Explorer 10 FPLC system. The
purification plot during ion exchange chromatographyand the SDS-PAGE of rLukS-PV following the ion ex-
change are shown (Figure 5). The SDS-PAGE of the
eluate from IEC showed that there was no band of
impurity above the 33 kDa band. However, the bands
of impurity below the 33 kDa band of the S subunit
were not removed by IEC. Obviously, further purification
treatment is required. Graves and colleagues found that a
second round of ion exchange chromatography was
necessary after the first attempt [42].
Table 4 Characteristics of mono S column used for ion
exchange chromatographya
Property Description
Dimensions 50 × 5 mm
Volume 1 mL
Flow rate 0.5-2 mL/min
Max. backpressure 750 psi (5 MPa)
Temperature 4°-40°C
pH 2-12
Approximate separation time 5 minutes
aThe manufacturers manual supports that Mono S column is compatible with
AKTA systems.
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ultimately
Running the same buffers as for the IEC with replacement
of Mono S column by HisPrep™ Superdex 30 column, re-
moved the rest of the impurities leaving the S subunit
ultra pure as bands of impurity were not seen on the
SDS-PAGE, neither above nor below the S subunit mark
(Figure 6). Size exclusion is a well known method of puri-
fying proteins according to molecular sizes. Exploiting the
interactions between poly-histidine fusion tags and immo-
bilized metal ions has been well documented [39]. Like
the 6His-LukF-PV subunit reported here, many proteins
have been purified successfully by single-step Nickel affi-
nity chromatography, including UreE [43]. Some proteins,
however, tend to elute with impurities after one chromato-
graphic treatment. LukS-PV from USA300 and USA400
did not become pure until after a second round of ion
exchange chromatography [42].Figure 5 Ion Exchange Chromatography (IEC) of 6His-LukS-PV. A AKTA
6His-LukS-PV. NOTE: The blue curve is the entire chromatographic plot itse
the green signal is the pressure. On the horizontal axis, the numbers in red
while the grey numbers (lower) is the timer (minutes). B Purity of 6His-LukS
had bands of impurity between the 33 kDa and 25 kDa Mw marks. Lane MMolecular weight (Mw) of peptides determined by
concordance between bioinformatics prediction, SDS-PAGE
and mass spectrometry
The translated protein sequences for rLukS-PV and for
rLukF-PV are presented in the additional file at the end of
the document (Additional file 1). The EXPASY predicted
Mw for the F peptide was 35645.41 Da and for the S pep-
tide was 33530.04 Da respectively. All the SDS-PAGE gels
were in concordance with the EXPASY prediction as the F
peptide was always far above the 33 kDa mark while the S
peptide was always close to the 33k Da mark in all the
SDS gels used in this work (Figures 3, 5 and 6). Results of
the structure prediction for the translated protein se-
quences are presented (Figure 7). The mass spectrometry
deconvolution data showed Mw of 33528.34 Da and
35643.57 Da for the S and F subunits respectively. To all
intents and purposes, the concordance between the
EXPASY prediction, the SDS-PAGE and the mass deter-
mination by MS suggests that all three tools could be re-
lied upon to predict, estimate or measure the Mw of PVL
subunits as long as the user understands the strengths and
limitations of each of the tools.
Conclusions
Our aim to provide biological tools for possible transla-
tion into anti-PVL therapy was driven by expert opinion
on the menacing PVL syndrome. As the risk level of
PVL-positive S. aureus is yet to be ascertained, manipu-
lations of the S. aureus substrain MW2 (USA400) from
NARSA were carried out in the BSL3. Given the several
life-threatening conditions associated with USA400 es-
pecially, we would rather apply higher safety precautionsExplorer chromatogram during ion exchange purification of
lf. On the vertical axis, mS/cm is the conductivity or absorbance, while
(upper) are the identification of the tubes containing the protein,
-PV following purification by IEC. Lanes 1, 2, 3 & 4, All of the eluate
, Protein Mw standard.
Figure 6 Size Exclusion Chromatography (SEC) of 6His-LukS-PV. A AKTA Explorer Chromatographic plot during SEC purification of 6His-LukS-PV.
NOTE: Vertical axis = absorbance, Horrizontal axis = Time (minutes). B Purity of 6His-LukS-PV following purification by SEC. Lane 1, 6His-LukS-PV
completely pure without bands of impurity; Lane 2, water; Lane 3, Total soluble lysate of E. coli BL21(DE3)pLysS-pET-21d(+)-lukS-PV after induction with
IPTG; Lane 4, E. coli BL21(DE3)pLysS-pET-21d(+)-lukS-PV before induction with IPTG, Lane M, Protein Mw standard.
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boratory users. This step was very important to us and
the outcome was quite rewarding as there has been no
record of our laboratory users/visitors, both the BSL3
and the BSL2, including the adjacent offices, coming
down with PVL-syndrome, even long after completion
of our experiments.
We are happy with the outcome of the DNA sequen-
cing and BLAST which we used to confirm molecular
identity at all necessary stages. The pET-21d(+) vector
was chosen because it carries an N-terminal T7•Tag® se-
quence and a C-terminal 6His•Tag® sequence. The T7
and 6His-Tag motifs are very important for expression
and for down-stream treatments including purification
by Nickel-affinity chromatography. Therefore, it was ne-
cessary to send the DNA out of our facility to be se-
quenced by the Cambridge Geneservice as they had the
T7 terminator primers which were not available in Not-
tingham at the time.Figure 7 Structures of 6His-LukSPV and 6His-LukF-PV as predicted by
(PS)2 (http://ps2.life.nctu.edu.tw/).The reliability of the BioLogic-LP and AKTA systems
to guide the progress of the purification cycle in real-
time is commendable. The purification plots showed
that the absorbance at any point during the elution cor-
related directly with the concentration of His-tagged
protein in the eluate (Figures 4, 5 and 6). Also, the SDS-
PAGE used to infer protein purity and molecular size
showed that the relative intensity of the protein bands
eluted from the system correlates with the AU observed
during the run. This is one of the innovative and user-
friendly features of modern chromatographic systems.
The fact that the experimenter can readily identify the
tube(s) containing the His-tagged proteins is very helpful
as it reduces waste of time and materials. Though the
initial cost of purchasing any of the modern chromato-
graphic instruments might be perceived as high, in the
end they are cost-effective.
Taken together, we engineered the lukS-PV and lukF-PV
genes respectively encoding the S and F subunits ofProtein Structure Prediction Server
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separate E. coli expression host systems. Having puri-
fied the pro-toxin subunits, we supplied them to the
Nottingham Cancer Immunotherapy group who used
them to establish anti-PVL monoclonal antibodies. We
are happy that the pro-toxin subunits have served as use-
ful input for the establishment of sequence-based diagnos-
tic and therapeutic tools for rapid and specific diagnosis
and abrogation of PVL-associated leukocytolysis and the
attendant rapid deterioration of its victims. In keeping
with the University of Nottingham policies on genetically
modified organisms, we handed over the engineered
E. coli clones expressing the PVL pro-toxin subunits,
namely E. coli BL21(DE3)-pET-21d(+)-lukS-PV and
E. coli BL21(DE3)-pET-21d(+)-lukF-PV, for LukS-PV and
LukF-PV respectively, to the Biosafety Officer (AC) for
safe-keeping.Additional files
Additional file 1: Direct strand sequence of rlukS-PV with
3ʹ terminal 6-CAC tag as present in the expression system.
Additional file 2: Direct strand sequence of rlukF-PV with
3ʹ terminal 6-CAC tag as present in the expression system.
Additional file 3: Peptide product (fusion LukS-PV), translated from
rlukS-PV, with C-terminal 6-Histidine tag as present in the
expression system.
Additional file 4: Peptide product (fusion LukF-PV), translated from
rlukF-PV, with C-terminal 6-Histidine tag as present in the
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